Sisters doing it for themselves

Journal of Family Planning and Reproductive Health Care

Volumn 35, Issue 2, 2009, Pages 71-72

  Szarewski, Anne ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

BLEEDING; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EXPOSURE; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; EMPOWERMENT; HEALTH EDUCATION; HUMAN; NAUSEA; NOTE; ORAL CONTRACEPTION; OVULATION INHIBITION; RISK BENEFIT ANALYSIS; SATISFACTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WITHDRAWAL BLEEDING;

CONTRACEPTIVES, ORAL, COMBINED; DECISION MAKING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MENSTRUAL CYCLE; PATIENT PARTICIPATION; WOMEN'S HEALTH;

EID: 65249109219     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118909787931933     Document Type: Note

References (11)

1. Gladwell M. John Rock's error. The New Yorker, 18 March 2000.
2. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78: 16-25.
3. Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008; 34: 237-246.
4. Edelman A, Gallo MF, Nichols MD, Jensen JT, Schulz KF, Grimes DA. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 2006; 21: 573-578.
5. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74: 439-445.
6. Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 2006; 195: 935-941.
7. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007; 75: 444-449.
8. Sulak PJ, Smith V, Coffee A, Witt I, Kuehl AL, Kuehl TJ. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008; 112: 563-571.
9. Electronic Medicines Compendium. NuvaRing: Summary of Product Characteristics. 23 January 2009. http://emc.medicines.org.uk/ document.aspx?documentld=21419 [Accessed 18 February 2009].
10. Glasier AF, Smith KB, van der Spuy ZM, Ho PC, Cheng L, Dada K, et al. Amenorrhea associated with contraception - an international study on acceptability. Contraception 2003; 67: 1-8.
11. Weisberg E. Judaism and women's health. J Fam Plann Reprod Health Care 2009; 35: 53-55.